跳至主要内容
临床试验/NCT01562639
NCT01562639已完成不适用

Nexium Capsules Specific Clinical Experience Investigation for Maintenance Therapy for Repeatedly Recurring/Relapsing Reflux Oesophagitis

AstraZeneca1 个研究点 分布在 1 个国家目标入组 647 人开始时间: 2012年4月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
AstraZeneca
入组人数
647
试验地点
1
主要终点
Number of Adverse Drug Reactions

研究概览

简要总结

The purpose of this study is to collect following data in patients given Nexium capsule (Nexium) in usual post-marketing use as the maintenance therapy for repeatedly recurring/relapsing reflux oesophagitis.

详细描述

Nexium capsules Specific Clinical Experience Investigation for Maintenance Therapy for Repeatedly Recurring/Relapsing Reflux Oesophagitis

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Patients with repeatedly recurring/relapsing reflux oesophagitis who will be given Nexium for the first time as a maintenance therapy.

排除标准

  • Patients having reflux oesophagitis when Nexium is started (Grade A, Grade B, Grade C or Grade D of Los Angeles Classification (Hoshihara's modification) on endoscopy)
  • Patients having previous history of maintenance therapy for repeatedly recurring/ relapsing reflux oesophagitis

结局指标

主要结局

Number of Adverse Drug Reactions

时间窗: 6 Month

Adverse event incidence

次要结局

  • Non-recurrence rate of reflux oesophagitis(6 Month)

研究者

发起方
AstraZeneca
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验